FindTrial
Sign In

The effect of prescribing aminophylline on the recovery of patients with acute COPD attack requiring noninvasive mechanical ventilation and investigating its effect on increasing the efficiency of the respiratory system

The effect of prescribing aminophylline on the recovery of patients with acute COPD attack requiring noninvasive mechanical ventilation and investigating its effect on increasing the efficiency of the respiratory system

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20241118063763N1
Enrollment
70
Registered
2025-03-30
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease. Chronic respiratory failure

Interventions

Intervention 1: Intervention group: Aminophylline is administered at a loading dose of 250 mg and a maintenance dose of 30 mg/hour. Intervention 2: Control group: Received standard treatment for an ac

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
42 Years to 90 Years

Inclusion criteria

Inclusion criteria: Age between 20 and 80 years. Have an acute attack of COPD. Require NIV treatment. No trauma or facial deformity. No severe decreased level of consciousness. No copious pulmonary secretions. No high risk of aspiration. No cardiorespiratory arrest.

Exclusion criteria

Exclusion criteria: No cardiovascular problems (heart failure, ischemia, arrhythmia, unstable hemodynamics resistant to treatment). No allergy to theophylline or aminophylline. No stomach ulcer. No pneumonia diagnosed in the chest X-ray. No lung malignancy. No decreased level of consciousness. No face or chest deformity. No asthma. No advanced malignancy of any type. No neuromuscular diseases or chest disorders. No pneumothorax. Not pregnant or breastfeeding. No persistent and frequent vomiting. Able to tolerate NIV. No history of theophylline use.

Design outcomes

Primary

MeasureTime frame
Examination of lung volume in the control and intervention groups. Timepoint: The effect of aminophylline after 3 days in the intervention group. Method of measurement: Examination of lung volumes through spirometry.;Examination of blood gases in two intervention and control groups. Timepoint: Investigating the effect of aminophylline on blood gases in the intervention group after 3 days. Method of measurement: Measurement by taking blood from the patient.;Examination of shortness of breath in two intervention and control groups. Timepoint: After the injection of the drug up to three days after the injection. Method of measurement: Borg questionnaire.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNoora Behzadian

Esfahan University of Medical Sciences

behzadiannoora@gmail.com+98 61 3333 2714

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026